Fact Sheet: Ocata Therapeutics (NASDAQ: OCAT)

Fact Sheet: Ocata Therapeutics (NASDAQ: OCAT) Jul 9, 2014 14:33:12 GMT asusdelux likes this

Post by JHam on Jul 9, 2014 14:33:12 GMT

"Ocata Therapeutics, Inc. (“Ocata”; NASDAQ Global Market: OCAT), formerly named Advanced Cell Technology, is a clinical stage biotechnology company focused on the development and commercialization of regenerative medicine and cell therapy technologies. The company’s most advanced products are in clinical trials for the treatment of Stargardt’s macular degeneration, dry age-related macular degeneration and myopic macular degeneration. Ocata’s preclinical programs involve cell therapies for the treatment of other ocular disorders and for diseases outside the field of ophthalmology, including autoimmune, inflammatory and wound healing-related disorders." (Source: company website)

Company website: www.ocata.com/

Presentations: www.slideshare.net/AdvancedCellTechnology & ir.ocata.com/events-presentations

SEC filings: www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001140098

Clinical trials

Dry Age-Related Macular Degeneration (Dry AMD)
clinicaltrials.gov/ct2/show/NCT01344993

Stargardt’s Macular Dystrophy (SMD)
clinicaltrials.gov/ct2/show/NCT01345006

Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (hESC-RPE) Cells in Patients With Stargardt's Macular Dystrophy (SMD)
clinicaltrials.gov/ct2/show/NCT01469832

Research With Retinal Cells Derived From Stem Cells for Myopic Macular Degeneration
clinicaltrials.gov/ct2/show/NCT02122159

Long Term Follow Up of Sub-retinal Transplantation of hESC Derived RPE Cells in Stargardt Macular Dystrophy Patients
clinicaltrials.gov/ct2/show/NCT02445612?term=ocata&rank=1

FactSheet (Pipeline & Upcoming Milestones):

*Courtesy of tradeup
** Updated 5/27/2015